Product logins

Find logins to all Clarivate products below.


Rheumatoid arthritis (RA) is a complex, chronic autoimmune condition that causes pain, stiffness, and swelling that, in moderate to severe cases, limits motion and functionality. The TreatmentTrends®: Rheumatoid Arthritis 2015 (EU5) report provides valuable insight into the treatment dynamics among more than 200 French, German, Italian, Spanish, and U.K. rheumatologists through comprehensive primary research methods and how these treatment dynamics have evolved in recent years. This report covers in detail the use of biological products prescribed for RA, and explores rheumatologists’ awareness, trial, and usage of currently available brands, as well as their familiarity with and interest in key emerging therapies.

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Current Treatment – Current Treatment: Physician Insights – Rheumatoid Arthritis (EU5)
Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-…
Report
Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
Report
Rheumatoid Arthritis | Disease Landscape & Forecast | G7 | 2024
Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…